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334National Cancer Institute, National Heart, Lung and
Blood Institute/Pediatric Blood and Marrow
Transplantation Consortium First International
Consensus Conference on Late Effects after Pediatric
Hematopoietic Cell Transplantation: The Need for
Pediatric-Specific Long-Term Follow-up Guidelines
Michael A. Pulsipher,1 Roderick Skinner,2 George B. McDonald,3 Sangeeta Hingorani,4
Saro H. Armenian,5 Kenneth R. Cooke,6 Clarisa Gracia,7 Anna Petryk,8 Smita Bhatia,5
Nancy Bunin,9 Michael L. Nieder,10 Christopher C. Dvorak,11 Lillian Sung,12
Jean E. Sanders,13 Joanne Kurtzberg,14 K. Scott Baker13Existing standards for screening and management of late effects occurring in children who have undergone
hematopoietic cell transplantation (HCT) include recommendations from pediatric cancer networks and
consensus guidelines from adult-oriented transplantation societies applicable to all HCTrecipients. Although
these approaches have significant merit, they are not pediatric HCT-focused, and they do not address post-
HCT challenges faced by children with complex nonmalignant disorders. In this article we discuss the
strengths and weaknesses of current published recommendations and conclude that pediatric-specific guide-
lines for post-HCT screening and management would be beneficial to the long-term health of these patients
and would promote late effects research in this field. Our panel of late effects experts also provides recom-
mendations for follow-up and therapy of selected post-HCTorgan and endocrine complications in pediatric
patients.
Biol Blood Marrow Transplant 18: 334-347 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Pediatric allogeneic transplantation, Pediatric autologous transplantation, Post-transplant
organ damageINTRODUCTION
In April 2011, the National Cancer Institute,
National Heart, Lung and Blood Institute, and Pediat-1Primary Children’s Medical Center, University of Utah
l of Medicine/Huntsman Cancer Institute, Division of
tology/BMT, Salt Lake City, Utah; 2Department of
atric and Adolescent Haematology and Oncology and
ren’s BMTUnit, Great North Children’s Hospital, Royal
ria Infirmary, Newcastle upon Tyne, United Kingdom;
roenterology/Hepatology Section, Clinical Research
on, Fred Hutchinson Cancer Research Center and Uni-
y of Washington School of Medicine, Seattle, Washing-
Department of Pediatrics, University of Washington,
on of Nephrology, Seattle Children’s Hospital, and Clin-
esearch Division, FredHutchinson Cancer Research Cen-
attle, Washington; 5Department of Population Sciences,
f Hope, Duarte, California; 6Department of Pediatrics,
on of Hematology/Oncology, Case Western Reserve
rsity, Rainbow Babies and Children’s Hospital, Cleve-
Ohio; 7Department of Obstetrics and Gynecology, Uni-
y of Pennsylvania, Philadelphia, Pennsylvania; 8Division
diatric Endocrinology, University of Minnesota Amplatz
ren’s Hospital, Minneapolis, Minnesota; 9Division of On-ric Blood and Marrow Transplant Consortium spon-
sored a consensus conference of international experts
in clinical and biological research into late effects aftercology, The Children’s Hospital of Philadelphia, Philadelphia,
Pennsylvania; 10Blood and Marrow Transplant Program, All
Children’sHospital, StPetersburg,Florida; 11DivisionofPediat-
ric Blood and Marrow Transplant, Benioff Children’s Hospital,
University of California San Francisco, San Francisco, Califor-
nia; 12Division of Haematology/Oncology, The Hospital for
Sick Children, Toronto, Canada; 13Clinical Research Division,
FredHutchinsonCancer ResearchCenter, Seattle,Washington;
and 14Pediatric Blood and Marrow Transplant Program, Duke
University Medical Center, Durham, North Carolina.
Financial disclosure: See Acknowledgments on page 344.
Correspondence and reprint requests: Michael A. Pulsipher, MD,
Division of Hematology/BMT, Primary Children’s Medical
Center, University of Utah School of Medicine/Huntsman
Cancer Institute, 50 North Medical Drive, Salt Lake City,
UT 84132 (e-mail: michael.pulsipher@hsc.utah.edu).
Received January 9, 2012; accepted January 11, 2012
 2012 American Society for Blood and Marrow Transplantation
1083-8791/$36.00
doi:10.1016/j.bbmt.2012.01.003
Biol Blood Marrow Transplant 18:334-347, 2012 335Guidelines for Follow-Up after HCT in Childrenhematopoietic cell transplantation (HCT) in children.
The goal of the conference was to review the current
state of knowledge and define gaps in the field, develop
consensus on critical areas for future research, and de-
termine the best study designs to effectively address
these questions. This is the final article in a published
series that addresses these goals in the following areas
for children undergoing HCT [1]: genetic risks of ex-
periencing late effects [2], methodological challenges
in late effects study designs [2], specific organ effects
[3], metabolic disorders [3], endocrine issues [4], im-
mune dysfunction and reconstitution [5], and quality
of life, functional, and neurocognitive outcomes [6].
The goal of this final article is to review and com-
pare current recommendations published by several
important groups for long-term follow up in some of
the aforementioned areas, adding updated recommen-
dations from the panel of experts that participated in
the conference. We also review the need for
pediatric-specific post-HCT guidelines. In doing so,
we recognize that many of these recommendations re-
quire further study to validate their clinical utility.
This issue is especially important in children. Al-
though several studies have identified increased risks
of mortality and a high incidence of late effects after
HCT in cohorts composed largely of adults [7-9],
only a handful of relatively small studies have focused
on children [10-14]. Many of the recommendations
that we review are based either on studies comprising
mainly adults or on survivor studies in children that
were not designed to specifically address unique
issues associated with HCT (eg, allogenicity,
prolonged altered immunity, graft-versus-host disease
[GVHD], specific effects of megadose therapy).Published Guidelines: Children’s Oncology
Group
The Children’s Oncology Group (COG) has pub-
lished a comprehensive series of recommendations
(‘‘Long-Term Follow-Up Guidelines for Survivors of
Childhood, Adolescent, and Young Adult Cancers,’’
version 3.0; available at www.survivorshipguidelines.
org). These guidelines are risk-based and exposure-
related. They come with a ‘‘patient-specific guideline
identification tool’’ that allows patients to define their
treatment era, tabulate cumulative exposures to che-
motherapeutic doses, identify sites and doses of radia-
tion exposure, verify whether they have undergone
HCT, list specific surgeries performed, and designate
whether they have receive other therapies (radioiodine
therapy or systemic metaiodobenzylguanidine ther-
apy). The tool then guides patients to sections that re-
view specific late effects associated with specific
exposures that they have experienced. These sections
describe the following: associated risk factors for the
effect, other potential late effects associated with thedescribed effect, the nature and recommended fre-
quency of specific evaluations by health care profes-
sionals, recommended health counseling, and links to
recommendations for cancer screening.
Various late affects after HCT are included in sec-
tions covering specific therapeutic exposures; for ex-
ample, endocrine effects are included in the total
body irradiation (TBI) section. In addition, there are
15 sections that focus on complications of HCT that
do not fit well into the therapeutic exposures model.
The HCT-specific sections address risks of secondary
cancers (eg, acute myelogenous leukemia, solid tu-
mors, lymphoma), hepatic toxicity, osteonecrosis,
and reduced bone mineral density (BMD) experienced
by HCT survivors. Problems associated with chronic
GVHD are also addressed, including complications
of the skin, eyes, and mouth; chronic pulmonary dis-
ease; immunologic dysfunction (with active GVHD);
esophageal and vaginal strictures/fibrosis; and joint
contractures.Published Guidelines: Center for International
Blood and Marrow Transplant Research,
American Society for Blood and Marrow
Transplantation, European Group for Blood and
Marrow Transplantation, Asia-Pacific Blood and
Marrow Transplantation Group, Bone Marrow
Transplant Society of Australia and New
Zealand, East Mediterranean Blood and Marrow
Transplantation Group, and Sociedade
Brasileira de Transplante de Medula Ossea
In 2011, the Center for International Blood and
Marrow Transplant Research (CIBMTR), American
Society of Blood and Marrow Transplantation
(ASBMT), European Group for Blood and Marrow
Transplantation (EBMT), Asia-Pacific Blood and
Marrow Transplantation Group (APBMT), Bone
Marrow Transplant Society of Australia and New
Zealand (BMTSANZ), East Mediterranean Blood
and Marrow Transplantation Group (EMBMT), and
Sociedade Brasileira de Transplante de Medula Ossea
(SBTMO) published ‘‘Recommended Screening and
Preventive Practices for Long-Term Survivors after
Hematopoietic Cell Transplantation’’ [15], an update
of guidelines originally published in 2006 by the
EBMT, CIBMTR, and ASBMT [16]. Because these
guidelines are applicable specifically to patients who
have undergone HCT, the authors chose to organize
screening recommendations by tissues and organs af-
fected, as well as by risks of secondary malignancies
and psychosocial harm, rather than the specific thera-
peutic exposures approach taken by the COG. Possible
late complications specific to each organ are listed,
along with risk factors such as age and radiation and
steroid exposure; recommendations for frequency of
screening are included as well.
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Adolescent Cancer Survivor Care and
Follow-Up Studies: Sorting Out Evidence
versus Opinion
The UK Children’s Cancer Study Group’s (now
known as Children’s Cancer and Leukaemia Group
[CCLG]) ‘‘Late-Effects Group Therapy-Based
Long-Term Follow-Up Practice Statement’’ (2nd edi-
tion, 2005; http://www.cclg.org.uk/dynamic_files/
LTFU-full.pdf) includes an appendix devoted
exclusively to comprehensive recommendations for
follow-up of survivors of childhoodHCT.Written us-
ing literature review and expert opinion, the appendix
is divided into systems (eg, endocrine), organs (eg,
skin), and functions (eg, quality of life), and includes
specific sections for secondary malignancies and
chronic GVHD. Causes and higher risk factors for
chronic toxicities are listed, and recommendations
for clinical evaluation, frequency of follow-up, and ini-
tial further actions are provided. Cross-references to
standard (ie, non-HCT) guidelines are provided where
appropriate. Although this document has the advan-
tage of being focused on the details and complex issues
of follow-up of pediatric HCT survivors, its current
utility is limited by the absence of formal evidence-
based methodology and of a recent update.
The Pan-European Network for Care of Survivors
after Childhood and Adolescent Cancer (PanCare),
established in 2008, has successfully obtained
European Union funding for the PanCare Childhood
and Adolescent Cancer Survivor Care and Follow-Up
Studies (PanCareSurFup) collaborative project. Among
several large epidemiologic studies, PanCareSurFup
will develop evidence-based pan-European guidelines
for long-term follow-up care of survivors of childhood
malignancy and of HCT. These guidelines will cover
clinical practice and organization of follow-up care, as
well as transition to age-appropriate care for survivors
approaching adulthood, and finally promotion of
a healthy lifestyle. The overall intention is to address
topics that are most important for survivors and their
families, and to facilitate optimal follow-up for each sur-
vivor in various countries with different levels of health
care resources and systems. The guidelines will be
developed with evidence-based methodology that
includes selection of appropriate topics and clinically
important questions to guide relevant literature
searches that will then inform the production of evi-
dence summaries. These summaries will then be used
to construct draft and, after appropriate peer review, re-
fine final practice recommendations. Although these
guidelineswill cover survivors of childhoodmalignancy
in general, particular attention will be given to includ-
ing late adverse effects suffered by pediatric HCT sur-
vivors and the follow-up needs of all of these survivors
(with both malignant and nonmalignant diseases).International Harmonization of Late-Effects
Follow-Up
Recent and ongoing initiatives are seeking to
achieve international harmonization of long-term
follow-up and surveillance recommendations for
survivors of childhood cancer.The existing pediatric
clinical guidelines mentioned earlier (ie, COG
and CCLG), as well as the Scottish Intercollegiate
Guidelines Network long-term follow up of survivors
of childhood cancer (2004; www.sign.ac.uk/pdf/
sign76.pdf) and the Dutch Childhood Oncology
Group’s ‘‘Long-Term Effects after Childhood’’ guide-
lines (http://later.skion.nl/), differ in their scope and
methodology. This has led to a variety of different rec-
ommendations. Despite the potentially different needs
of different countries and health care settings, there are
advantages and efficiencies in collaborative efforts to
share evidence, workload, and conclusions. Recent
work by the foregoing groups and several other na-
tional late-effects group representatives has led to the
development of harmonized breast cancer surveillance
recommendations for survivors of childhood cancer,
identifying which survivors should be screened and
how, when, and how often to screen. These recom-
mendations have been developed in such a manner as
to permit implementation in variety of health care
and resource settings. The next planned step is to de-
velop analogous recommendations for cardiomypathy
screening, which is clearly of major importance for
many survivors of HCT. Other future topics are being
selected in an ongoing Delphi survey.
Comparison of Screening Recommendations:
Do They Meet the Needs of the Pediatric HCT
Survivor?
The COG and CCLG guidelines are designed to
comprehensively address all modalities of cancer ther-
apy and recognize differences in late effects noted
based on therapeutic technique, treatment era, dose,
and developmental stage in children. They are very
straightforward for children who receive a small num-
ber of agents followed by local surgery or radiation.
Themajor challenge faced in applying these guidelines
to the pediatric HCT population is that themajority of
patients undergoing HCT have been treated with
a large number of agents both before and after a first
relapse, and sometimes subsequent relapses. As a result
some children may be at greater risk for worsening or-
gan damage with the megadose therapy of HCT be-
cause of preexisting treatments; thus, listing effects
due to a single agent does not adequately reflect the to-
tal effect of anHCT regimen. Furthermore, over time,
the ability to delivery HCT safely to higher-risk chil-
dren who have received more regimens and potentially
multiple transplantations has increased. Adverse
effects of HCT are expected to be worse in these
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Figure 1. Late effects after HCTare a result of the interaction of pre-
HCTexposures to chemotherapy, radiation, and surgery with the trans-
plantation conditioning regimen, acute complications of transplantation,
and transplantation-specific complications, such as acute and chronic
GVHD, persistent immunodeficiency, and so on. The risks for these out-
comes are alsomodified by other intrinsic and extrinsic factors (age, sex,
genetics, social, comorbidities, lifestyle) that can alter these risks in
either a positive or a negative manner.
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may include genetics, age, sex, lifestyle, and existing
comorbidities. Finally, transplantation-specific effects,
such as altered immunity and GVHD, along with pro-
longed exposure to immunosuppressive agents, signif-
icantly changes a patient’s long-term risk profile; for
example, prolonged prednisone exposure dramatically
affects growth and bone health, and prolonged intense
immune suppression affects the risk of second malig-
nancy (Figure 1). Although the COG and CCLG
guidelines partially address some of these issues in
their HCT-specific sections, the complexity of the
problem makes addressing these issues in a compre-
hensive way challenging.
A further practical challenge with using the COG
guidelines for transplantation-specific late effects is
that these specific guidelines are very difficult to glean
from this enormous work. For example, challenges
post-HCT patients experience with growth failure
are spread out among the many therapeutic exposures
that pre-HCT patients have, and the task of pulling
things together for these very complex patients is
daunting. Finally, the COG and CCLG guidelines
are strongly oriented toward children with cancer,
but more than one-third of pediatric HCT patients
undergo the procedure due to nonmalignant indica-
tions.
The CIBMTR/ASBMT/EBMT/APBMT/BMT
SANZ/EMBMT/SBTMO guidelines (herein after
termed the ‘‘joint transplant society guidelines’’) ap-
proach the subject in a very practical, although less
comprehensive fashion. Broad guidelines applicable
to the most common late effects noted after HCT
are included. Specific types and timing of follow-
up are outlined, and numerous transplantation-
specific references are included. This approach
makes it easier for both patients and practitioners
to identify the major issues that should be covered
in a follow-up visit for a patient who has undergone
HCT. Caveats include the fact that the guidelines do
not address the many differences in outcomes that
can occur after HCT based on pre-HCT therapies
and comorbidities. In addition, these simpler general
guidelines do not account for exploration of differ-
ences in degree of intensity of preparative regimens
used, extent of GVHD and post-HCT immune sup-
pression undergone, different outcomes based on the
use of different stem cell sources, and risks based on
age, specific nonmalignant disorder of the recipient,
or other factors.
With the strengths and weaknesses of the pub-
lished recommendations in mind, Table 1 compares
the COG, joint transplant society, and CCLG recom-
mendations for specific areas, along with specific rec-
ommendations from our panel of experts based on
updated evidence. There are many areas not addressed
in this table that should be included in comprehensiveguidelines (eg, screening for second malignancies;
neurocognitive, functional, and quality of life effects;
consequences of prolonged immune deficiency).Post-HCT Follow-Up Guidelines Specific to
Pediatric Patients
We have outlined strengths and weaknesses of cur-
rent published recommendations for long-term follow
up of children who have undergone HCT. The most
significant weakness of both the pediatric-specific can-
cer recommendations and the joint transplant society
guidelines for pediatric HCT patients is that they do
not contain detailed information needed for long-
term follow up of children undergoing HCT for non-
malignant disorders. Many nonmalignant conditions
require unique disease-specific follow-up (eg, bone
and neurocognitive challenges inHurler syndrome, in-
creased second cancer risk in Fanconi anemia). The
absence of these recommendations in current guide-
lines is a major gap, given that up to one-third of pedi-
atric HCTs are performed in children with these
disorders. With these issues in mind, ideal pediatric-
specific post-HCT follow-up guidelines should ac-
complish the following: (1) provide evidence-based
recommendations for screening and intervention that
consider both pre-HCT treatment and underlying ge-
netic disorders; (2) be sufficiently accessible for use by
local physicians, yet have depth and secondary re-
sources available that will nurture research and cater
to the needs of specialized late-effects clinics; (3) use
vigorous methodology according to recognized stan-
dards, such as Appraisal of Guidelines Research and
Evaluation (www.agreecollaboration.org) to foster in-
ternational utilization and comparative studies aimed
Table 1. Selected Screening Recommendations for Late Effects after HCT in Pediatric Patients
COG Recommendations
Joint Transplant Society
Recommendations*
UK CCLG Practice Statement, BMT
Section†
Expert Panel Recommendations
Screening Management
Iron overload HCT Section 95.
Aspartate aminotransferase, alanine
aminotransferase, bilirubin, ferritin
screening at start of follow-up and
as needed. Biopsy, chelation, and
phlebotomy as indicated.
Serum ferritin at 1 year after HCT in
patients who received RBC
transfusions. Consider liver biopsy
or imaging studies for abnormal
results based on magnitude of
elevation and clinical context;
subsequent
monitoring is suggested for patients
with elevated liver function tests,
continued RBC transfusions, or
presence of hepatitis C infection.
History and physical examination,
liver function tests yearly; ferritin
as needed.
Annual serum ferritin; if elevated,
consider T2* MRI.
Phlebotomy or chelation.
Gastrointestinal HCT Section 95.
Aspartate aminotransferase, alanine
aminotransferase, bilirubin, ferritin
screening at entry into follow-up
and as needed. Hepatology
consultation for persistent
abnormal liver function tests.
Hepatitis B and C viral testing as
indicated.
Liver function tests every 3-6 months
in the first year, then individualized,
but at least yearly thereafter.
Monitor viral load by polymerase
chain reaction for patients with
known hepatitis B or C virus
infection, with liver and infectious
disease specialist consultation.
Consider liver biopsy at 8-10 years
after HCT to assess cirrhosis in
patients with chronic hepatitis C
infection.
Required only in the presence of
overt symptoms. History and
physical examination. High index of
suspicion for chronic GVHD in
patients with cholestasis or acute
hepatitis.
Microbiological, virologic, and
biochemical investigation of
malabsorption if present.
Annual screening for chronic GVHD;
hepatitis virus infection screening;
annual hepatocellular carcinoma
screening for high-risk patients:
 Hepatitis C or hepatitis B infection
 Obesity, diabetes
 Low platelet count.
Renal Chemotherapy, Alkylating Agents
Section 13.
Risks: therapy with ifosfamide,
cisplatin, carboplatin,
aminoglycosides, amphotericin,
immunosuppressants, X-ray
therapy of kidney. Screen with
electrolytes/blood urea nitrogen/
creatinine urinalysis at entry into
follow-up and as needed.
Treatment includes electrolyte
supplementation, nephrology for
hypertension, proteinuria,
progressive renal insufficiency.
Blood pressure assessment at every
clinic visit, with aggressive
hypertension management
Assess renal function with blood urea
nitrogen, creatinine, and urine
protein at 6 months, 1 year and at
least yearly thereafter. Consider
further workup (kidney biopsy or
renal ultrasound) for further
workup of renal dysfunction as
clinically indicated.
Blood pressure, screen for
hematuria/proteinuria (if protein
positive, check urine protein:
creatinine ratio), blood urea
nitrogen/creatinine yearly.
Consider glomerular filtration rate
measurement if creatinine is high.
High index of suspicion for chronic
GVHD in patients with proteinuria
or nephrotic syndrome.
Monitor urine for albumin:creatinine
ratio at day 80 and then annually; if
ratio is $30 and <300 mg/g,
confirm with 2 or more tests in 3-6
months and monitor every 3-6
months; if ratio is >300 mg/g,
monitor every 3-6 months.
Treat with angiotensin converting
enzyme inhibitor or angiotensin
receptor blocker if albumin:
creatinine ratio is >300 mg/g on
one occasion or if patient has
persistent ratio >30 g/kg on 3
occasions in a 6- month period and
has hypertension.
Pulmonary HCT Section 101.
Risks: chest x-ray therapy/TBI,
bleomycin, busulfan, BCNU,
CCNU, chronic GVHD. Screen
with chest x-ray and pulmonary
function testing at entry into
follow-up and as needed. Avoid
smoking; caution with scuba diving
and anesthesia. Administer
influenza and pneumococal
vaccination.
Routine clinical evaluation at 6
months and 1 year after HCTand at
least yearly thereafter. Assessment
of tobacco use and counseling
against smoking. Pulmonary
function testing and focused
radiologic assessment for
allogeneic HCTrecipients.
History and physical examination;
pulmonary function tests at 1 year
(subsequent frequency depends on
results and presence/absence of
symptoms). Chest X-ray; consider
high-resolution computed
tomography if symptomatic or if
pulmonary function tests are
significantly abnormal. High index
of suspicion for chronic GVHD.
Advise against tobacco use;
recommend influenza and
pneumococcus immunization.
Pulmonary function testing for
allogeneic recipients twice per year
for 2 years, with consideration for
more frequent screening in
recipients of mismatched or
unrelated donor grafts, or patients
with active chronic GVHD. After 2
years, consider yearly follow-up
pulmonary function tests based on
symptoms and past measurements.
With a >15% decrease in pulmonary
function test values or new
pulmonary infiltrate, evaluate for
infection/GVHD. Refer to
pulmonologist for disease-specific
care as needed.
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Cardiac XRT Section 71: Multiple cardiac
effects (eg, congestive heart failure,
cardiomyopathy). Risks higher with
previous use of anthracyclines or
combined with cyclophosphamide
as conditioning for HCT. Screen
with baseline echocardiogran/
electrocardiogram, fasting glucose/
lipid profile every 2 years.
Recommendations for screening
and treatment based on condition
and total anthracycline dose.
Routine clinical assessment of
cardiovascular risk factors as per
general health maintenance at 1
year and at least yearly thereafter.
Education and counseling on ‘‘heart
healthy’’ lifestyle (eg, regular
exercise, healthy weight, no
smoking, dietary counseling). Early
treatment of cardiovascular risk
factors, such as diabetes,
hypertension, and dyslipidemia.
Administration of antibiotics for
endocarditis prophylaxis according
to American Heart Association
guidelines.
Echocardiography annually if
abnormal, every 3-5 years if
normal. If heart included in
radiotherapy field at any time
(including TBI), consider review of
other risk factors (eg, measure
fasting lipids). Advise against
tobacco. No other
recommendations specific to
HCT.‡
Annual ca iovascular risk
assessm t; blood pressure each
visit and t least annually;
electroc rdiogram/
echocar iogram at least every 5
years, m re frequently if patient
receive nthracycline, TBI, or
chest ir diation.
Refer to cardiologist for abnormal or
declining cardiac function.
Metabolic XRT Section 49: Metabolic Syndrome
as a Possible Late Effect of TBI.
Screen with height, weight, blood
pressure, and body mass index
yearly plus fasting glucose/lipid
profile every 2 years. Treatment
with diet, counseling, physical
activity.
Screening for cardiovascular risk
factors as outlined in the Cardiac
section.
Measure fasting blood glucose, fasting
lipids, hemoglobin A1c yearly;
perform glucose tolerance test if
fasting glucose elevated.
Lipid profi and fasting glucose at
least ev y 5 years; if abnormal,
screen nually.
No transplantation-specific
recommendations available.
Thyroid dysfunction XRT Section 64/65: Hypothyroidism/
Hyperthyroidism.
Risks: X-ray therapy $10 Gy, thyroid
in field. Yearly screening, more
frequently during rapid growth.
Thyroid function testing yearly
post-HCT, or if relevant symptoms
develop.
Thyroid-stimulating hormone and
free thyroxine yearly; palpate
thyroid yearly. Measure thyroid
autoantibodies if thyroid function
tests are abnormal. Perform
ultrasound scan and refer for fine-
needle biopsy if thyroid nodule
palpated.
Thyroid-st ulating hormone and
free thy xine annually for 10 years
after bu lfan and for at least 30
years af r TBI. Physical
examina on of thyroid yearly to
screen r tumors after TBI.
If thyroid-stimulating hormone is high
and free thyroxine is normal, either
treat or repeat in 2 months.
Replace thyroid as indicated for
low levels.
Rare secondary thyroid tumors post-
TBI can be cured with surgery.
Growth impairment XRT Section 50: Growth Hormone
Deficiency.
Risks: young age, TBI $10 Gy single
fraction, $12 Gy fractionated.
Screen with dietary assessment,
height, weight, and body mass
index every 6 months until growth
completed. Refer to an endocrine
specialist for height <3rd
percentile, a drop of $2% in
ranking, growth velocity <4-5 cm/
year, or lack of growth spurt.
Pediatric recipients: Monitoring of
growth velocity in children
annually; assessment of thyroid and
GH function if clinically indicated.
Measure height and weight, calculate
height velocity every 3-6 months
until puberty and growth
completed.
Measure insulin-like growth factor 1
and bone age in TBI recipients if
concerned about growth. Refer to
pediatric endocrinologist for
consideration of dynamic GH
testing in TBI recipients with slow
growth (height velocity <25th
percentile).
Accurate easurement of growth
yearly t ough full growth (age 17
years fo girls and 19 years for
boys). B ne age as needed.
Bone age and referral to an endocrine
specialist for a patient not growing
appropriately. GH therapy may
unmask hypothyroidism.
(Continued )
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Table 1. (Continued )
COG Recommendations
Joint Transplant Society
Recommendations*
UK CCLG Practice Statement, BMT
Section†
Expert Panel Recommendations
S eening Management
Low BMD HCT Section 97.
Risks: young age, Caucasian, low body
mass index, steroids, calcineurins,
cranial X-ray therapy/TBI, GH
deficiency, delayed puberty,
hyperthyroidism, poor exercise,
poor nutrition, smoking, alcohol
use, carbonated beverages. Dual-
energy X-ray absorptiometry at
entry into long-term follow-up and
as needed. Treatment with vitamin
D, calcium, and exercise. Consult
with an endocrine spcialist for
osteoporosis/history of fractures.
Dual-photon densitometry at 1 year
for adult women, all allogeneic
HCTrecipients, and patients at high
risk for bone loss; subsequent
testing determined by defects or to
assess response to therapy.
Treatment with physical activity,
vitamin D, and calcium
supplementation to prevent loss of
bone density. In patients with
chronic GVHD, consider dual-
photon densitometry at an earlier
date in patients with prolonged
corticosteroid or calcineurin
inhibitor exposure.
History, examination (fractures, back
pain). Consider measurement of
BMD or dual-energy X-ray
absorptiometry scan, especially in
patients treated for GH deficiency
or hypogonadism.
Dual-energy X ay absorptiometry
scan before T, 1 year after HCT,
yearly if z-sc e is <-1.
Patients with z-score <-2, history of
fractures: refer to endocrine
specialist. Calcium and vitamin D
supplementation, weight-bearing
exercise. Avoid smoking, alcohol,
caffeine.
Osteonecrosis HCT Section 96.
Risks: age$10 years at HCT, steroids,
TBI, focal x-ray therapy, allogeneic
> autologous, chronic GVHD.
Screen yearly with examination and
MRI as clinically indicated.
MRI to evaluate patients
with joint symptoms.
History, examination.
MRI if suspicion of osteonecrosis.
Refer patients with osteonecrosis to
orthopedic surgeon.
Consider MRI reen of
asymptomat patients on
high-dose st oids. Early MRI
screening of ny patients with
symptoms o oint pain, pain in
groin or ant ior thigh, limping.
Minimize steroids and alcohol
consumption, offer analgesics,
non–weight-bearing exercise,
physical therapy. Refer to
orthopedic specialist.
Reproductive risks Chemotherapy, Alkylating Agents,
Section 7.
Risks: combined doses of alkylators/
heavy metals/dacarbazine/
temazolamide with X-ray therapy
to cranium or gonads. Screen FSH,
leutinizing hormone, testosterone,
Tanner staging at age 13-14 and as
clinically indicated for delayed
puberty, irregular menses. Semen
analysis; repeat as indicated
because resumption can occur 10
years after treatment.
Consider referral to appropriate
specialists for patients who are
contemplating a pregnancy or are
having difficulty conceiving.
Counsel sexually active patients in
the reproductive age group about
birth control post-HCT.
Assess pubertal stage every 3-6
months until puberty and growth
completed. Measure sex hormones
(testosterone or estradiol), FSH,
leutinizing hormone, and inhibin B
(if available) yearly from age 10
years. Suggest semen analysis when
appropriate. At the appropriate
time, discuss risk of impaired
fertility, adverse pregnancy
outcomes, and early menopause;
discuss advisability of using
contraception even with impaired
fertility; discuss referral to
reproductive medicine specialist
for consideration of assisted-
reproduction technology when
appropriate. Refer patients with
Leydig cell or ovarian failure to
endocrinologist for hormone
treatment.
Women: moni r for ovarian failure
(FSH; assess ycling). Men: semen
analysis.
Women: Anti-Mullerian hormone
may assess ovarian reserve. Treat
ovarian failure with hormone
replacement therapy.
Men: If oligospermia noted, may offer
intracytoplasmic sperm injection.
*Recommendations from the CIBMTR, ASBMT, EBMT, APBMT, BMTSANZ, EMBMT, and SBTMO.
†Further information about higher-risk factors and further actions is provided in each section.
‡Cross-references to the Cardiac section of the Practice Statement.
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revisions on a scheduled basis as ongoing studies lead
to new recommendations for intervention. We recom-
mend a coordinated effort through the Pediatric Blood
and Marrow Transplant Consortium, the COG Stem
Cell Transplantation Committee, the CCLG Bone
Marrow Transplantation subgroup, the EBMT Pedi-
atric Diseases Working Group, and other pediatric-
oriented HCT-specific groups, working in parallel
with larger pediatric cancer late effects groups (eg,
COG Late Effects Task Force, PanCareSurFup, In-
ternational Harmonization Collaboration) to formu-
late these guidelines.
Recommendations for Follow-Up in Selected
Areas from Our Consensus Panel Experts
Iron overload, gastrointestinal, and hepatobiliary
issues
Secondary iron overload is a nearly universal com-
plication of HCT, causing liver-, cardiac-, pancreatic-,
pituitary-, and thyroid-related morbidity. Risk factors
include a high number of red cell transfusions and
increased gastrointestinal absorption of iron due to in-
flammatory conditions, including GVHD [17]. Studies
using serum ferritin as amarker have suggested that iron
levels fall slowly over time after transplantation,
reaching normal levels years later [18,19]. In heavily
iron-overloaded patients, iron reduction therapy may
improve transplantation outcomes [20] and cardiac
function [21]. Because of this, it is important to screen
for iron overload after HCT using serum ferritin.
Although liver biopsy is typically recommended
to quantify iron overload, the recently standardized
T2*-weighted magnetic resonance imaging (MRI)
technique will likely replace this for managing
patients. The mainstay of treatment of iron overload
is phlebotomy in patients with recovered normal
erythropoiesis [22].
The majority of gastrointestinal late effects are re-
lated to protracted acute GVHD and chronic GVHD.
As GVHD is controlled and tolerance is developed,
most symptoms resolve. Major hepatobiliary concerns
include the consequences of viral hepatitis acquired
before or during transplantation, biliary stone disease,
and focal liver lesions [23]. Screening andmanagement
of viral hepatitis should distinguish this from GVHD
presenting with hepatocellular injury, and should in-
volve a hepatologist.
Renal disease
Hypertension and renal function screening should
occur at all long-term follow-up visits. As outlined in
our earlier description of renal dysfunction [3], albu-
minuria and proteinuria may reflect GVHD-induced
endothelial injury, inflammatory tubular and intersti-
tial damage, and progressive chronic kidney disease;however, whether albuminuria or proteinuria by them-
selves cause the increased morbidity and mortality of
HCT or merely reflect other processes is not known.
Regardless, because albuminuria and proteinuria may
predict poor late outcomes, it is worthwhile to screen
for these disorders and consider referral to a nephrolo-
gist for patients with these and other signs of ongoing
renal disease. It is also important to aggressively treat
hypertension in patients after HCT, especially those
treated with prolonged courses of calcineurin inh-
ibitors. Whether HCT recipients with albuminuria
and hypertension benefit from treatment with an
angiotensin-converting enzyme inhibitor or angioten-
sin receptor blocker requires further study, but careful
control of hypertensionwith captopril did show a bene-
fit in a small study [24], and larger studies are underway.
Pulmonary disease
Early recognition and treatment of chronic pulmo-
nary conditions after HCT may be important to suc-
cessful outcomes, and thus increased surveillance for
lung dysfunction by serial pulmonary function tests
for the first 2 years after HCT should be considered
whenever feasible. Screening before onset of symp-
toms is important; by the time patients become symp-
tomatic, the disease is generally advanced [25].
Comprehensive evaluation is recommended when pul-
monary function test values are decreased by.15% or
when signs or symptoms of pulmonary dysfunction are
detected [26,27]. Testing should include a high-
resolution computed tomography scan of the chest
and bronchoalveolar lavage analysis exclude opportu-
nistic infections if applicable. In consultation with
a pulmonologist, lung biopsy may helpful in making
definitive diagnoses when necessary.
Standard treatment for obstructive lung disease
combines enhanced immunosuppression with sup-
portive care, including antimicrobial prophylaxis,
bronchodilator therapy, and supplemental oxygen
when indicated. Unfortunately, the response of pa-
tients with restrictive lung disease to multiple agents,
including corticosteroids, cyclosporine, tacrolimus,
and azathioprine is limited [28]. The potential role
for tumor necrosis factor a in the pathogenesis of
both obstructive and restrictive lung disease suggests
that neutralizing agents, such as etanercept, may have
promise [29]. The combination of azithromycin, mon-
telukast, and inhaled fluticasone is currently being
investigated to prevent the progression of newly diag-
nosed bronchiolitis obliterans [30].
Cardiac disease/metabolic syndrome
Although cardiac dysfunction has been studied ex-
tensively in non-HCT settings, less is known regarding
the incidence and predictors of congestive heart failure
after HCT in childhood. Potentially cardiotoxic
exposures unique to HCT include conditioning with
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mide) and TBI [31]. In addition, HCT survivors are
at increased risk for developing cardiovascular risk fac-
tors, such as hypertension and diabetes, due in part to
exposure to TBI, prolonged immunosuppressive ther-
apy after allogeneic HCT, or other health conditions,
such as hypothyroidism or growth hormone (GH) de-
ficiency [31,32]. In addition, pre-HCT exposures and
cardiac function have been shown to have a significant
impact on post-HCT cardiac function, so levels of pre-
HCT anthracycline and chest irradiation should be
known as post-HCT patients are evaluated for long-
term issues [33]. Althoughmore specificwork is needed
to verify this, current evidence suggests that the risk
for late-occurring cardiovascular complications after
HCT may be due largely to pre-HCT therapeutic ex-
posures, with little additional risk from conditioning-
related exposures or GVHD [33-35].
Screening and follow-up for cardiac/metabolic
syndrome issues should include blood pressure assess-
ment, measurement of lipid profile and fasting glucose
every 5 years or yearly if abnormal, and treatment of
lipid abnormalities based on current cardiovascular
guidelines. Electrocardiography and echocardiogra-
phy should be performed at appropriate intervals based
on pre-HCT exposure to anthracyclines and chest wall
irradiation.
Thyroid dysfunction
Given that we do not yet know the full impact of
the various reduced-intensity and nonmyeloablative
HCT regimens on the development of thyroid dys-
function, all patients should be monitored. The cur-
rent recommendations are that thyroid function
studies (ie, thyroid-stimulating hormone and free thy-
roxine) should be performed annually post-HCT [16],
and patients with abnormal values should be referred
to pediatric endocrinologists. If thyroid-stimulating
hormone is elevated with a normal free thyroxine,
then thyroid hormone replacement could be initiated
[16], but because subclinical hypothyroidism may re-
solve spontaneously [36], the studies also could be sim-
ply repeated in approximately 2-6 months. Patients
starting on thyroid replacement should be followed
with a repeat level 6 weeks later and then twice yearly
in postpubertal patients and every 3-4 months in pre-
pubertal or pubertal patients [16]. In patients receiving
busulfan-based conditioning, surveillance needs to
continue for at least 10 years after HCT [37]. How-
ever, in patients who received TBI, there is no clear
plateau in the incidence out to 30 years [37], suggesting
that screening may need to be continued for life. For-
tunately, the development of thyroid tumors (median
onset, 10 years post-HCT; range, 4.5-22.3 years) is
rare and seems to occur only in patients who received
TBI (3% incidence) [37]. In patients who received
TBI, careful physical examination of the thyroid glandis mandatory, and thyroid ultrasound should be per-
formed as clinically indicated [37].
Growth impairment
The current recommendations are to measure
children’s growth annually with an accurate stadiome-
ter and calculate growth velocity [16]. Patients exhibit-
ing slow growth should also have an annual bone age
determination until epiphysial closure occurs (gener-
ally around age 17 for girls and age 19 for boys). For
those children who do not appear to be tracking along
an appropriate growth curve, referral for pediatric
endocrinology consultation is appropriate.
The use of recombinant GH therapy to treat
growth impairment due to GH deficiency has not
been universal. Clearly, the administration of GH ap-
pears to improve final height compared with controls
who underwent similar transplantations and chose
not to receive GH [38,39]. The treatment effect was
strongest in those aged \10 years at the time of
HCT, whereas an effect of GH on older children
was difficult to ascertain [39]. One concern regarding
the use of GH is that using an agent that stimulates
the growth of cells may play a role in the development
of relapse of the patient’s underlying malignant disease
or of a secondary malignancy. Fortunately, the data do
not support this concern, although clearly the develop-
ment of benign osteochondromas or exostoses are
more common in GH-treated patients [39]. Interest-
ingly, GH treatment also may reveal previously unrec-
ognized hypothyroidism, highlighting the importance
of routine monitoring of all aspects of the endocrine
system [39].
Bone health: low BMD
Given the limitations of existing studies specific to
pediatric HCT, the recommendations for follow-up
are based on a general knowledge of modifiable risk
factors, similar to those published recently [40,41].
Patients should be encouraged to maintain an
adequate intake of calcium and vitamin D [42,43]
and should be counseled about adverse effects of
cigarette smoking as well as alcohol and caffeine
consumption [41]. Weight-bearing exercise, early
mobilization, and return to normal activities should
be encouraged as well.
The appropriate time to initiate screening for low
BMD and the appropriate frequency of screening after
HCT are currently unclear. Until more data are avail-
able, general guidelines for monitoring BMD in
children and adolescents should be followed [44],
including annual age-appropriate monitoring of
growth, thyroid function, and pubertal development.
We also recommend dual-energy X-ray absorptiome-
try scan before HCT, 1 year after HCT, then once
a year if BMD z-score is \21 or every 5 years if
BMD z-score is normal. Patients exposed to high doses
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significant bone loss (BMD z-score\22), history of
fractures, or endocrine deficiencies should be referred
to a pediatric endocrinologist. Correction of hormonal
deficiencies (eg, hypogonadism, GH deficiency)
should be done if deemed appropriate based on age
and the risk-to-benefit ratio. We also recommended
checking serum calcium, magnesium, and 25-hydroxy-
vitamin D level in HCT recipients, particularly in
those with low BMD [45].
Bisphosphonates have been shown to be effective
in preventing bone loss after HCT in adult pa-
tients [46,47]. The primary mode of action of
bisphosphonates is inhibition of bone resorption by
osteoclasts [48]. Although whether bone resorption is
increased in children after HCT is unclear, one study
reported that bisphosphonate therapy can improve
BMD in pediatric HCT recipients as well [45]. More
studies are needed to determine whether the use of
bisphosphonates can be recommended as a routine
measure in children who underwent HCT who either
have low BMD or are at increased risk for continued
bone loss (eg, those receiving corticosteroid treatment
for GVHD). Potential concerns about the use of
bisphosphonates in children have been reviewed by
Ward et al. [49].
Bone health: osteonecrosis
MRI screening of patients receiving high-dose ste-
roids has allowed identification of osteonecrosis in the
early, asymptomatic stages [50]. Although the disease
progresses in the vast majority of cases [51], small, cen-
tral lesions away from weight-bearing areas may de-
crease or remain stable over time [52,53]. Rarely,
spontaneous regression has been reported [54].
Involvement of a pediatric orthopedic surgeon is
key to managing patients with osteonecrosis. Before
subchondral fracture and collapse occur, whether to
treat asymptomatic patients is controversial, given
that the natural history of asymptomatic disease is
poorly understood. Several temporary measures have
been recommended [55-57], including minimizing
exposure to corticosteroids, minimizing alcohol
consumption, use of analgesics for pain relief, limited
weight-bearing, and physical therapy to design appro-
priate non–weight-bearing exercise (eg, swimming).
Prolonged limited weight-bearing might not be prac-
tical in the pediatric population, however.
In symptomatic patients, treatment is targeted at
joint preservation and pain control. Core decompres-
sion involves opening a tract into the necrotic bone
to reduce intraosseous pressure and stimulate healing.
Although this procedure can effectively relieve pain,
a large percentage of patients will progress to subchon-
dral fracture. Several pharmacologic approaches show
promise in more effectively preventing osteonecrosis
or slowing its progression, although the data are lim-ited. Lipid-lowering agents, such as statins, may be
beneficial, with evidence pointing to a pathogenic
role of hyperlipidemia [58-60], but another study
found no such association [61]. In addition, statins
may increase bone formation and improve BMD
[62]. Low molecular weight heparin also may be con-
sidered to target hypercoagulability in osteonecrosis
[63], although there is a concern regarding a possible
increased risk of osteoporosis [64]. Bisphosphonates
may be used to improve the biomechanical properties
of bone and prevent or delay bone collapse early in the
disease course, as well as for pain control [65-67].
However, the safety and efficacy of bisphosphonates
in children at risk for osteonecrosis has not been
studied except for traumatic osteonecrosis in
adolescents [68]. Recently, cellular therapy using au-
tologous marrow-derived mesenchymal stem cells
[69,70] has been proposed based on the finding of
a decreased stem cell population in the marrow
adjacent to osteonecrotic sites [71].
After subchondral fracture and collapse, arthritis
leading to joint destruction is inevitable, with debilitat-
ing loss of ambulatory function. Unfortunately, cur-
rently the only reliable means of eliminating pain
and restoring function is replacement of the affected
joint. Joint replacement offers an excellent functional
outcome and is the standard of care in skeletally ma-
ture patients; however, the limited long-term durabil-
ity of prosthetic joints in young adults makes this an
unattractive option. In skeletally immature patients,
joint replacement is deferred, and attempts are made
to control pain with analgesics and activity modifica-
tions. The effectiveness of these nonsurgical interven-
tions is poor, however.
Given these potential treatments, annual hip and
knee MRI should be considered for high-risk children
aged.8 years for up to 3 years after HCT or when in-
dicated by clinical symptoms (eg, joint pain, pain in the
groin or anterior thigh, limping) [57,72]. Guidelines
and consensus on treatment of osteonecrosis after
diagnosis are lacking, however.
Reproductive risks
For males, reproductive function should be evalu-
ated by assessing sexual function and performing a se-
men analysis. In women, menstrual function should be
assessed, although hormonal contraception will mask
any signs of ovarian failure. Even womenwhomaintain
cyclic menses after therapy are at risk for early meno-
pause, infertility, and long-term health problems
related to early ovarian failure [73-76]. Several
hormones and ultrasound studies have been used to
evaluate a woman’s fertility potential and response to
fertility treatments, including early follicular phase
measures of serum follicle-stimulating hormone
(FSH), inhibin B, and anti-Mullerian hormone, as
well as ultrasound measures of ovarian volume and
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these parameters may be impaired in survivors [77-
81]. Of these, it appears that anti-Mullerian hormone
and antral follicle count are the most sensitive mea-
sures of ovarian reserve [82]. Ongoing prospective
studies of ovarian reserve at the University of Pennsyl-
vania have identified impaired ovarian reserve in men-
struating HCT survivors who were exposed to more
intense conditioning regimens. Although these tests
might help determine ovarian reserve in transplant re-
cipients, whether they will ultimately help predict the
likelihood of pregnancy or time to menopause in this
population is not clear.
Early loss of ovarian function is associated with
menopausal symptoms and long-term health risks, in-
cluding cardiovascular disease and osteoporosis.
Estrogen therapy is the most effective treatment for
menopausal symptoms and genitourinary atrophy,
and these symptoms dramatically improve in trans-
plant recipients started on hormone therapy [83]. In
addition, data in women with premature ovarian fail-
ure due to bone marrow transplantation show that
HT improves BMD [84]. Although therapeutic op-
tions for the treatment of early ovarian failure in fe-
males who have completed puberty may include
combined hormonal contraception or hormone re-
placement [85], there are no clear guidelines regarding
the optimal method of hormone replacement therapy
in this population, given the sparse data comparing
the long-term safety and efficacy of various different
forms of hormone therapy in cancer survivors. Impor-
tantly, the results of large hormone therapy trials, such
as the Women’s Health Initiative, cannot be general-
ized to the population of young cancer survivors with
premature ovarian failure where the benefits of hor-
mone therapy usually outweigh potential risks. Prepu-
bertal HCT recipients should be closely monitored for
development of secondary sexual characteristics after
10-11 years of age. A patient with evidence of gonadal
failure should be under the care of a pediatric endocri-
nologist, who can administer a physiological regimen
of hormone replacement therapy to ensure optimal de-
velopment of secondary sex characteristics and adult
stature [86].
Males with oligospermia as a result of previous
cancer therapy may be able to donate for intrauterine
insemination or in vitro fertilization with intracyto-
plasmic sperm injection. In the setting of azoospermia
due to testicular failure after cancer therapy, donor
sperm may be the sole available option. Menstruating
women found to have decreased ovarian reserve after
cancer treatment may be candidates for fertility ther-
apy with ovulation induction, intrauterine insemina-
tions, or in vitro fertilization. However, existing data
suggest that cancer survivors have a diminished re-
sponse to ovarian stimulation and a lower in vitro fer-
tilization success rate compared with couples withouta history of cancer [87]. After a woman has experienced
reproductive dysfunction as a result of cancer treat-
ment, the optionwith the highest chance of a delivering
a live-born infant is a donor egg. In cases where the
HCT recipient is not sufficiently healthy to consider
pregnancy herself [32] or is unable to successfully carry
a pregnancy because of previous cancer treatments,
gestational surrogacy may be considered. Finally, em-
bryo donation and adoption are other options that
HCT survivors may consider.
Although HCT often leads to ovarian failure and
infertility, unintended pregnancies may occur even in
patients presumed to have ovarian failure [88]. Because
HCT survivors may have comorbidities that compli-
cate pregnancy, discussion of family planning and con-
traceptive options should be a priority. Contraceptive
choices may be limited for this population, given that
a history of thromboembolic disease, significant liver
dysfunction, or other comorbidities may make
estrogen-containing hormonal contraception unsafe.
Although barrier and progestin-containing contracep-
tives may be reasonable choices for such patients, other
effective methods include intrauterine devices and
sterilization procedures [89].Whether intended or un-
intended, pregnancies in HCT survivors should be
considered ‘‘high-risk’’ because of an increased risk
of miscarriage and a high risk of preterm delivery
[90]. Children born to survivors do not appear to be
at increased risk for birth defects, however [90].CONCLUSION
Outstanding resources exist to assist practitioners
in caring for pediatric survivors of HCT. Significant
efforts to standardize late effects follow-up and foster
late effects research are underway. These efforts would
be greatly enhanced by pediatric-specific guidelines
for follow- up after HCT designed with the goal of im-
proving the long-term care and overall health of chil-
dren who have undergone this procedure.ACKNOWLEDGMENTS
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